CDA | Evidence Driven
CDA | Evidence Driven

Lenvima for Hepatocellular Carcinoma – Details

Details

Files
Generic Name:
Lenvatinib
Project Status:
Complete
Therapeutic Area:
Hepatocellular Carcinoma (HCC)
Manufacturer:
Eisai Limited
Brand Name:
Lenvima
Project Line:
Reimbursement Review
Project Number:
PC0175-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
4 mg & 12 mg
Tumour Type:
Gastrointestinal
Indications:
Hepatocellular Carcinoma
Funding Request:
For the first-line treatment of adult patients with unresectable Hepatocellular Carcinoma (HCC)
Sponsor:
Eisai Limited
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Lenvatinib (Lenvima) HCC – pERC Final Recommendation Final Recommendation July 24, 2019 View PDF
Lenvatinib (Lenvima) HCC – Final Economic Guidance Report Guidance Reports July 24, 2019 View PDF
Lenvatinib (Lenvima) HCC – Final Clinical Guidance Report Guidance Reports July 24, 2019 View PDF
Lenvatinib (Lenvima) HCC – pERC Initial Recommendation Initial Recommendation July 5, 2019 View PDF
Lenvatinib (Lenvima) HCC – PAG Feedback on Initial Recommendation Feedback July 24, 2019 View PDF
Lenvatinib (Lenvima) HCC – Manufacturer Feedback on Initial Recommendation Feedback July 24, 2019 View PDF
Lenvatinib (Lenvima) HCC – Patient Advocacy Group Feedback on Initial Recommendation Feedback July 24, 2019 View PDF
Lenvatinib (Lenvima) HCC – Clinician Feedback on Initial Recommendation Feedback July 24, 2019 View PDF
Lenvatinib (Lenvima) HCC – Patient Advocacy Group COI Declarations COI Declarations July 24, 2019 View PDF
Lenvatinib (Lenvima) HCC – Clinician COI Declarations COI Declarations July 24, 2019 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : August 13, 2019